Pratyush Kumar Sahoo

Mr. Pratyush Kumar Sahoo


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 September 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Jyothilakshmi SajimonJyothilakshmi Sajimon
Jyothilakshmi Sajimon
PSPratyush Kumar Sahoo
Pratyush Kumar Sahoo
NBNeeha Sinai Borker
Neeha Sinai Borker
RARifat Aara
Rifat Aara
RNRadhika Nair
Radhika Nair
Breast cancer therapy has advanced substantially over the past two decades, yet disease recurrence and metastatic progression remain the leading causes of mortality. Resistance in hormone receptor-positive (HR+), HER2-positive, and Triple-negative (TNBC) disease is conventionally treated as three separate, each driven by its own escape route. This review suggests that resistance across all three subtypes instead converges on a shared, limited set of adaptive programs: epithelial-mesenchymal plasticity, cancer stem cell enrichment, metabolic rewiring, and microenvironment-mediated immune evasion. We trace the stage-wise clinical trajectory and dominant point of failure within each subtype, then examine how large-cohort genomics, single-cell transcriptomics, circulating tumour DNA, and machine learning have exposed this convergence, and the barriers still limiting its clinical use. To move beyond a purely mechanistic argument, we present an exploratory analysis stratifying overall survival within each subtype by which adaptive program dominates the resistant tumour. EMT enrichment in TNBC, immune evasion in HR-positive disease, and metabolic rewiring in HER2-positive disease. Although based on modest cohorts, this pattern suggests the four programs are genuinely different drawing on a shared cellular toolkit, rather than interchangeable descriptions of the same biology, and supports testing metabolic-program enrichment as a maintenance biomarker in HER2-positive disease. Closing the gap between mechanistic knowledge and clinical practice will require replacing subtype-exclusive resistance biomarkers with subtype anchored program-specific panels deployed alongside the standard clinical panel, shifting management from a model that reacts to resistance toward one that anticipates it.